Post by icemandios on Apr 17, 2023 12:38:20 GMT
Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity
PR Newswire
- Data to be presented at American Association for Cancer Research (AACR) Annual Meeting 2023 -
MARLBOROUGH, Mass. , April 17, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that in vivo data from a hepatocellular carcinoma model provides insight into the mechanism by which locally administered mouse-targeted PH-762 (mPH-762) exerts systemic anti-tumor efficacy ("abscopal effect").
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
In the study, intratumoral administration of mPH-762 stimulated a local anti-tumor immune response and generated systemic tumor-reactive memory T cells, suggesting that the abscopal effects of PH-762 are mediated by the immune system.
"These preclinical study results support intratumoral use of PH-762 in the clinical setting, with deeper understanding of the mechanism of abscopal efficacy," said Dr. Mary Spellman , Phio's Acting Chief Medical Officer. "In addition, immune-related adverse events noted with systemic PD-1 inhibition may be mitigated by intratumoral administration."
PH-762 is under clinical development in a phase 1b trial for neoadjuvant treatment of advanced resectable melanoma.
Poster Title: Intratumoral PH-762, a self-delivering RNAi therapeutic (INTASYL™) targeting mouse PD-1, generates systemic tumor-specific memory CD8 T cells, providing a mechanism for abscopal efficacy toward untreated tumors in a murine hepatocarcinoma model.
Session Date and Time: Monday, April 17, 2023 from 9:00 AM - 12:30 PM EST
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
PR Newswire
- Data to be presented at American Association for Cancer Research (AACR) Annual Meeting 2023 -
MARLBOROUGH, Mass. , April 17, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that in vivo data from a hepatocellular carcinoma model provides insight into the mechanism by which locally administered mouse-targeted PH-762 (mPH-762) exerts systemic anti-tumor efficacy ("abscopal effect").
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
In the study, intratumoral administration of mPH-762 stimulated a local anti-tumor immune response and generated systemic tumor-reactive memory T cells, suggesting that the abscopal effects of PH-762 are mediated by the immune system.
"These preclinical study results support intratumoral use of PH-762 in the clinical setting, with deeper understanding of the mechanism of abscopal efficacy," said Dr. Mary Spellman , Phio's Acting Chief Medical Officer. "In addition, immune-related adverse events noted with systemic PD-1 inhibition may be mitigated by intratumoral administration."
PH-762 is under clinical development in a phase 1b trial for neoadjuvant treatment of advanced resectable melanoma.
Presentation Details:
Poster Title: Intratumoral PH-762, a self-delivering RNAi therapeutic (INTASYL™) targeting mouse PD-1, generates systemic tumor-specific memory CD8 T cells, providing a mechanism for abscopal efficacy toward untreated tumors in a murine hepatocarcinoma model.
Session Date and Time: Monday, April 17, 2023 from 9:00 AM - 12:30 PM EST
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.